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Liver firewall function at the heart of mutualism between the host and 
its commensal intestinal microbes 
 
 
Abstract: 
A prerequisite for establishment of mutualism between the host and the dense microbial 
community that inhabits the lower large intestine is the stringent mucosal 
compartmentalization of microorganisms. Intestinal dendritic cells (DC) sample live 
microbes to induce mucosal immunity – microbe-loaded DC trafficking through 
lymphatics are arrested at the mesenteric lymph nodes (MLN), which constitute the 
firewall of the intestinal lymphatic circulation. We show that the liver, which receives the 
intestinal venous blood, is positioned as a vascular firewall if microbes enter the 
bloodstream in situations of intestinal pathology. The two firewalls act independently for 
lymphatic sampling and vascular translocation into intestinal venous blood respectively. 
Phagocytic Kupffer cells in the liver also clear commensals from the systemic 
vasculature independently of the spleen through the liver’s own arterial supply. Damage 
to the liver firewall in mice impairs functional clearance of commensals from blood, 
despite heightened innate immunity, resulting in spontaneous priming of non-mucosal 
immune responses through increased systemic exposure to intestinal commensals. 
Systemic immune responses consistent with increased extraintestinal commensal 
exposure were also found in humans with liver disease (non-alcoholic steatohepatitis). 
Bacterial infections are the commonest cause of death in cirrhosis and the liver is a 
functional vascular firewall at the centre of host-microbial mutualism, required to clear 
commensals that penetrate either intestinal or systemic vascular circuits. 	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Introduction: 
Liver disease is dramatically increasing in incidence in the developed world, secondary not only 
to alcohol abuse and viral infections but also to progressive hepatic fatty change and damage 
arising from a metabolic syndrome.  All forms of chronic liver disease, including non-alcoholic 
fatty liver disease (NAFLD), potentially lead to cirrhosis and liver failure. Even with very mild liver 
disease, such as excess fatty accumulation in the liver, the structure of the sinusoids and 
Kupffer cell function are compromised (1-3). Cirrhosis imposes dramatically increased resistance 
to blood flow in the hepatic portal vein: the resulting increased pressure (portal hypertension) 
causes enlargement of the spleen, damage to the intestine and abnormal vascular channels 
(shunts) where the portal circulation bypasses the liver and drains directly into the inferior vena 
cava returning blood to the heart. Despite the fearsome metabolic complications of liver failure, 
the commonest cause of death in patients with terminal cirrhosis is from infections (4). Many of 
these infections are derived from oral or intestinal commensal organisms, resulting in peritonitis, 
spontaneous bacterial empyema or bacteraemia (5), so understanding the impact of liver 
function and dysfunction on host-microbial mutualism is highly relevant to human health. 
 
Mesenteric lymph nodes are known to act as a firewall during the induction of mucosal immunity 
through the DC/lymphatic route in healthy mice with a normal intestinal mucosa (6). We have 
previously shown that live commensal bacteria are sampled by intestinal dendritic cells (DC), 
which can traffic to the mesenteric lymph nodes (6, 7). These intestinal DC normally do not 
penetrate further to reach systemic secondary lymphoid structures (6), thus induction of 
intestinal mucosal immune responses are compartmentalized to the intestinal mucosal immune 
system. 
The liver receives both venous blood from the intestine via the hepatic portal vein, and arterial 
blood from the hepatic artery arising from the celiac trunk of the aorta. Although the liver is 
ideally positioned as a second firewall for commensals that succeed in reaching the mesenteric 
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or systemic vasculature, and dynamic studies have shown that its abundant Kupffer 
macrophage population can capture pathogens from the blood (8, 9), it has been unclear 
whether it has an obligatory role to limit penetration of commensal microbes that are sampled in 
the course of inducing normal mucosal immune responses. Here we show that the liver remains 
sterile when benign intestinal commensals are sampled through the lymphatic route in the 
healthy mouse intestine. However, the liver becomes important as an independent second 
firewall when commensal microbes penetrate the vasculature of the inflamed intestine or when 
commensal microbes have to be cleared from the systemic blood. In both animal models and 
human patients with liver disease, loss of this central firewall function progressively disrupts host 
microbial mutualism by increasing systemic exposure and systemic immune activation to 
intestinal commensals. 
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Results: 
To determine whether the liver is also acting as a firewall during sampling of intestinal 
commensal bacteria in healthy wild-type mice we compared numbers of culturable bacteria in 
the mesenteric lymph nodes and the liver over time after gavaging germ-free mice with the 
reversible colonisation strain E. coli HA107 (10) or its parent strain JM83. In each case, live 
commensal bacteria penetrated to the mesenteric lymph nodes, from lymphatic trafficking of 
intestinal dendritic cells carrying commensals sampled at the intestinal epithelial surface (6, 7) 
(Fig. 1A). In contrast, the liver remained entirely sterile throughout the experiment (Fig. 1A). 
Similarly, (n=3) or in experiments designed to detect portal bacteraemia at earlier times live 
bacteria were never recovered from the portal blood in these mice (fig. S1A), suggesting that 
extremely efficient bacterial killing in the liver does not explain the lack of live bacterial recovery. 
Despite no penetration of live bacteria to the liver or induction of systemic immune responses (6,	  
10) after intestinal challenge in healthy mice, we could demonstrate drainage of bacterial 
breakdown products to hepatic tissues after gavage of E. coli JS219 metabolically labelled 
during growth in the presence of [14C]glucose (Fig. 1B). Therefore the penetration of live 
organisms to the mesenteric lymph nodes during induction of mucosal immunity can be 
uncoupled from penetration to either the liver or the spleen in a healthy animal, despite 
substantial accumulation of metabolites originating from intestinal bacteria in both organs. This 
suggests that in healthy animals, the liver is not a required part of the firewall that 
compartmentalises lymphatic-based mucosal immune induction, but rather functions for 
processing and detoxification of bacterial-derived material, or as a second firewall for those 
microbes that enter the mesenteric blood vessels as a result of increased epithelial penetration 
or during mucosal damage. 
 
Venous blood from the intestine drains mainly to the liver via the hepatic portal vein, which is 
formed by the confluence of the superior mesenteric vein and the splenic/inferior mesenteric 
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vein (fig. S1B). To test the role of the liver as a firewall for the mesenteric vasculature, 
commensals were deliberately injected into the hepatic portal venous system: these were 
primarily cleared to the liver and to a minor extent to the spleen (Fig. 1C). As model commensal 
microbes do not penetrate to the liver when given as intestinal challenge doses to healthy 
pathogen-free mice, we next tested the effect of inducing intestinal inflammation. After treatment 
with dextran sodium sulphate (DSS), an intestinal dose of bacteria that would normally only 
penetrate within dendritic cells to the mesenteric lymph nodes, now consistently reached the 
liver (Fig. 1D) and in some animals could be detected in the spleen and peripheral blood (fig. 
S2A). We concluded that whilst the liver is not part of the firewall required to compartmentalize 
the mucosal lymphatics in healthy SPF mice, it is a vital vascular firewall for the mesenteric 
circulation, and likely critical to maintain mutualism in conditions of weakened mucosal-blood 
barrier function. 
 
We next considered the role of the liver in clearing commensal microbes from the general 
systemic vasculature (not just the mesenteric/portal intestinal blood vessels). It is well 
documented that the spleen filters microorganisms within the general blood circulation: we have 
previously shown that live commensals given into the tail vein are cleared into the spleen, with 
only small numbers reaching the lymph nodes (6). However, splenectomy can be carried out in 
humans or experimental animals with relatively little disturbance in host-microbial mutualism 
provided there has been pre-immunization against encapsulated bacteria (11). The main 
vascular exchange structures of the liver – hepatic sinusoids – are a capillary level confluence of 
branches of the hepatic portal vein (which receives the splenic vein as a tributary) and the 
hepatic artery (fig. S1B) (12). This anatomical arrangement caused us to question whether the 
liver functions at the heart of host-commensal mutualism by clearing microbes within the general 
systemic vasculature through two possible routes: i) directly through filtration of blood from the 
hepatic artery, or ii) indirectly by filtering any overflow from the spleen or transit through 
	   7	  
mesenteric vessels via the splenic→hepatic portal vein. Liver sinusoids are lined by enormous 
numbers of Kupffer cell phagocytes, which constitute over 80% of all tissue macrophages in the 
body and about 20% of all hepatic cells and which are present in normal numbers in germ-free 
animals (13, 14). These are capable of taking up and killing microorganisms that they encounter 
(8, 9, 15,	  16). Indeed, we found that doses of commensals given intravenously caused culturable 
commensals to be detected in the liver of wild-type mice, and this effect was not significantly 
different in splenectomised mice (Fig. 1E), verifying an effective systemic vascular clearance to 
the liver, independently of the spleen, probably mostly through the hepatic blood supply. We 
then examined the role of the hepatic arterial supply in delivering commensals to the liver in 
animals where the spleen is present.  After ligating the hepatic artery (a non-essential vascular 
supply of the liver) prior to administering the venous dose of commensals clearance to the liver 
was significantly reduced compared with sham-operated animals in which the artery was 
exposed but not ligated (Fig. 1F) and clearance from the blood was also delayed (3 hours: 
ligated 203 ± 69 CFU/50 µl versus sham 41 ± 26 CFU/50 µl, mean ± SD, n=5). The liver 
therefore forms a critical part of the filtration system that clears systemic commensal 
bacteraemia through both the arterial and portal venous circuits.  
 
To address the function of the liver in clearing, as opposed to merely capturing commensals that 
have reached the systemic circulation, we carried out trajectory experiments to measure the 
presence of commensals in the peripheral general circulation over time following an 
experimental intravenous dose. We started by asking whether depletion of Kupffer cells in the 
liver would impair the clearance of commensals from the general vasculature independently of 
the spleen. To do this, clodronate liposomes were injected into C57BL/6 mice to deplete 
phagocyte populations, after prior splenectomy (17). Even in the absence of the spleen, 
clodronate treatment resulted in delayed clearance of bacteremia from a challenge dose of E. 
coli K-12 (Fig. 2A, fig. S2B) given three days later into the tail vein. Although there is probably a 
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small effect of macrophages outside the liver, hepatic Kupffer cells form the majority of body 
macrophages and culture experiments showed that >86% of culturable model commensal 
bacteria were recovered from either the liver or spleen following intravenous challenge in wild-
type unmanipulated animals. Given that there is also delayed clearance of commensals from the 
peripheral general vasculature in the setting of liver disease (Fig. 2B, fig. S3A-C) and that mice 
with liver disease show increased liver bacterial burdens after intravenous bacterial challenge 
(fig. S3D), we concluded that bacterial clearance by Kupffer cells in the liver is an important 
mechanism for the removal of live commensals from the blood, mirroring their role in dynamic 
studies of pathogen clearance.  
 
To examine the effects of liver dysfunction on host microbial mutualism specifically, we studied 
two independent models of liver disease. First, we measured the trajectory of clearance of 
challenge doses of E. coli K-12 in cirrhotic mice following bile duct ligation (BDL) compared with 
sham-operated controls. This showed significantly reduced efficiency of clearance of commensal 
bacteria from the blood and spleen of cirrhotic mice (Fig. 2, B and C). This was observed despite 
a dramatic increase in the number of blood granulocytes in the circulation of BDL mice (fig. S4A) 
and evidence of stronger release of acute phase proteins (Lipocalin2) into the serum (fig. S4B). 
Therefore, despite heightened inflammatory responses to challenge, liver disease was 
associated with a strong reduction in bacterial clearance ability of the mice. As bile-duct ligation 
in mice induces cholestasis and thus altered bile salt recycling and some degree of intestinal 
pathology, we used an additional model of liver disease that allowed us to study the trajectory of 
host microbiota mutualism in liver disease. Clearance of an intravenous challenge dose of 
bacteria from the blood, liver and spleen was also delayed if the liver was damaged using 
carbon tetrachloride (CCl4) treatment (causing less severe hepatic fibrosis at early stages)	   (18) 
(Fig. 2D, fig. S3 and S5). Importantly, CCL4 treated mice showed normal distribution of liver 
Kupffer cells on histological specimens supporting the concept of altered phagocytic capacity 
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rather than simply disrupted liver architecture, reduced numbers of immune cells and fibrotic 
replacement in liver disease (fig. S5D).  
 
We speculated whether this altered bacterial clearance ability during murine liver disease could 
be due to “exhaustion” of the innate immune system by accumulated bacterial products in the 
systemic circulation. To investigate this possibility, we serially pretreated mice with increasing 
doses of Salmonella-LPS over 21 days (to match the timing of bacterial challenge in BDL mice 
after surgery). However, when these preconditioned mice were challenged with an intravenous 
dose of a non-pathogenic E. coli they displayed greatly enhanced bacterial clearance compared 
to control animals, despite non-cross-reactivity between the LPS used for pre-treatment and that 
of the challenge strain (Fig. 2, E and F, fig. S6, A and B). An expansion of blood granulocytes 
was also observed in LPS-conditioned mice (data not shown). Therefore increased exposure to 
microbial products alone was insufficient to cause the observed commensal clearance defects, 
in the absence of liver disease. We also considered whether the integrity of the mesenteric 
lymph node firewall was impaired in the setting of liver disease. We verified that an intestinal 
challenge dose of E. coli reached the mesenteric lymph nodes equivalently whether or not there 
was hepatocellular damage in the CCl4 model, but there was no further penetration to the 
thoracic duct lymph, showing that the mesenteric firewall remained intact (fig. S6C). These 
defects of clearance of commensal bacteria from the systemic circulation could be detected in 
acute CCl4 liver disease in mice colonized with a strict altered Schaedler flora (ASF; a very 
simple benign microbiota consisting of 8 microbial species) and with no evidence for dysbiosis or 
defects in mesenteric lymph node barrier function or intestinal integrity (fig S6C and S7A). More 
advanced liver disease (such as observed in BDL) certainly causes secondary histological 
damage to the intestine (fig. S7B) as well as low-grade intestinal inflammation measured 
through the fecal content of the neutrophil activation marker lipocalin-2 (fig. S7C) as a result of 
the effects of increased pressure in the portal circulation. Therefore in the face of advancing liver 
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disease, there is a combination of increased probability of intestinal microbes translocating into 
the vasculature and decreased ability to clear these microbes from portal or systemic blood. 
 
To follow the functional consequences of liver dysfunction on host-microbial immune mutualism 
in both mouse and human we needed to interrogate low levels of systemic exposure to intestinal 
commensal microbes independently of intestinal or systemic challenge doses in both murine 
models of liver disease and in human patients. To do this, we made use of immunoglobulin 
isotype differences that occur when commensal bacteria induce immune responses in different 
body compartments (19). We have previously demonstrated that the response to commensals 
typically found in SPF mice is compartmentalised to the mucosa and hence to mucosal IgA (6, 
19). Serum IgG against commensals can be experimentally induced by deliberate injection of 
commensal organisms into the tail vein, but is absent from specific-pathogen free (SPF) wild-
type mice (19). Anti-commensal serum IgG also occurs spontaneously in mice that inefficiently 
clear commensals (defective Toll-like receptor signalling resulting from MyD88/TRIF adaptor 
deficiency or in mice deficient in the enzyme pathways required to generate oxygen or nitric 
oxide radicals for biocidal activity in phagocytes), as live commensals can then reach and induce 
immunity in systemic secondary lymphoid structures (20). Therefore, the presence of high titres 
of specific serum IgG directed against commensal microbes can be used as a surrogate marker 
of commensal penetration to the systemic immune system. 
 
To validate the concept of examining induction of specific serum IgG against dominant intestinal 
commensals, we used a trajectory of exposure to CCl4 as a sequential progressive model of liver 
disease. In early liver disease, specific serum IgG against commensals of the microbiota were 
absent, but these appeared as the liver disease progressed, measured using a specific FACS-
based assay which assesses specific surface Ig binding to the endogenous microbes (20), 
normalised for total IgG concentration (Fig. 3, A to F). Specific serum IgG against commensal 
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microbes, such as autologous Lactobacillus sp. or bulk cultured aerobes was also increased in 
mice or rats with a more diverse microbiota that had developed fibrosis following bile duct 
ligation (Fig. 3, E and F, fig. S8).  
 
A critical issue in modelling human disease is that rodent models of cirrhosis develop over 
weeks and months, compared with human disease that can develop over decades. The question 
was whether early liver disease in humans (with its associated microvascular and phagocytic 
abnormalities (1, 3)) is associated with abnormalities of handling and compartmentalising 
intestinal commensals, or whether disturbance of host-microbial mutualism only develops with 
very advanced liver pathology. To address this we assembled two separate cohorts of patients, 
from different University Hospitals in Italy and Switzerland. In the first cohort, we compared 
patients with non-alcoholic fatty liver disease and matched control patients. In the second we 
were able to examine patients with liver steatosis, non-alcoholic steatohepatitis (NASH) and 
cirrhosis compared with controls. In most cases of liver steatosis or NASH the patient has no 
symptoms of the disease and there is no metabolic liver failure, although some cases will later 
progress to cirrhosis. Strikingly, in both cohorts, these early cases of human liver disease also 
had evidence of increased serum IgG and IgA responses against both aerobic and anaerobic 
non-pathogenic intestinal commensals independently of the stage of disease (Fig. 4A and S9A) 
and Euclidean heatmaps of the responses were also discriminatory for diagnosis in unbiased 
cluster analysis (Fig. 4B and S9B). This suggests that impaired liver phagocyte capture of 
bacteria is a likely contributor to human liver disease that exacerbates other features of the 
underlying etiology.   
As early stages of disease are not associated with porto-systemic vascular shunting or drastic 
metabolic failure of the liver, we concluded that disrupted host-microbiota mutualism is amongst 
the earliest consequences of human liver disease.  
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Discussion: 
We have found that compartmentalisation of commensal intestinal microbes is defective in 
animal models of liver disease. Interestingly, this was not due to loss of function in the well-
described primary lymphatic firewall that functions during normal mucosal sampling of intestinal 
bacteria, but due to failure of a hepatic vascular firewall that is required to clear blood-borne 
commensals from the mesenteric and systemic vasculature efficiently. Disturbed 
compartmentalization during murine liver dysfunction resulted in spontaneously increased 
systemic immune responses to resident commensals without intestinal challenge or overt 
intestinal pathology. This is consistent with bacterial exposure of the systemic lymphoid 
structures secondary to increased penetration and reduced commensal clearance from the 
vasculature despite increased innate immune activity. As murine and human liver disease is 
associated with increased complement activity (21), impaired liver bactericidal capacity is likely 
to be a major contributor to increased systemic commensal bacterial exposure in liver disease. 
In human patients, similar systemic immune responses to commensals are observed very early 
in the course of the human condition long before cirrhosis has developed. Even though it was 
not possible to collect patient fecal samples in order to normalize to each patient’s microbiota 
composition, we found systemic immune responses against a selection of non-pathogenic 
commensal bacteria to be discriminatory for diagnosis in unbiased cluster analysis. It is known 
that dysbiosis of intestinal microbes can precede and trigger liver damage (22, 23): this is also 
likely to be an initiating event in at least some human patients, although it is not required per se 
for the disturbance in host microbial mutualism as in our mouse model the very simple ASF 
microbiota was tightly controlled and liver damage was provoked by other methods. Thus we 
were able to separate dysbiosis from the direct effects of liver disease on systemic bacterial 
handling. This revealed a critical requirement for liver ultrastructure and function to clear bacteria. 
Our observations in human liver disease highlight that such mechanisms are essential to 
maintain normal host-microbiota homeostasis in the context of frequent “real-world” challenges 
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to intestinal integrity. It is possible that monitoring anti-microbiota IgA and IgG titres in liver 
patients may identify those with the highest risk of infectious complications and may thus have 
diagnostic value. Failed compartmentalization and vascular clearance of commensals are likely 
to be important factors resulting in catastrophic infective complications of patients with end-stage 
liver disease such as spontaneous bacterial peritonitis and sepsis which is predominantly 
caused by organisms of intestinal origin. 
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Materials and Methods: 
Animal experiments. Liver fibrosis models: For analysis of serum anti-microbiota antibodies, 
BDL treatments were performed at Ghent University Hospital, Belgium in C57BL/10 mice as 
described previously (24). Briefly, a midline abdominal incision was made and the common bile 
duct was isolated and occluded with a double ligature of a non-resorbable suture. The first 
ligature was made below the junction of the hepatic ducts and the second was made above the 
entrance of the pancreatic duct. The common bile duct was sectioned between the two ligatures 
and mice were euthanized 6 weeks after BDL. In sham-operated mice, ligatures were placed 
identically but no section was made. CCl4 was administered intra-peritoneally in C57BL/6 mice 
colonised with an Altered Schaedler flora consisting of 8 bacterial species (Actobacillus 
acidophilus (strain ASF 360), Lactobacillus salivarius (strain ASF 361), Bacteroides distasonis 
(strain ASF 519), Flexistipes sp. (ASF 457), Clostridium cluster XIV group (ASF 356, ASF 492, 
ASF 500 and ASF 502)) twice weekly (1:4 dissolved in olive oil; 60 µl per animal), whereas 
control animals received 60 µl olive oil. Mice were analysed after 6, 12 and 16 weeks. 
For bacterial clearance measurements, A. DeGottardi performed BDL treatments in gnotobiotic 
NMRI mice in Bern, as described above. Mice were analysed 3 weeks after surgery.  
Rat bile-duct ligation was performed as described previously (25). 7 weeks old male Wistar rats 
(Charles River) were housed in IVC cages at the University Bern.  
LPS pre-conditioning experiments: Swiss Webster mice housed under ultraclean conditions at 
the ETH Zürich department of microbiology were treated 3 times per week with PBS alone or 
with 1 µg LPS from Salmonella Typhimurium intraperitoneally  and analysed 48h after the final 
treatment.  
DSS-colitis induction: 14 weeks old SPF C57BL/6 mice were treated with 3 cycles of DSS 
(molecular weight 36’000 – 50’000, MP) in drinking water for 5 days (Week 1: 1% DSS, week 2: 
1.5% DSS, week 3: 2% DSS) followed by 4 days of normal drinking water. All mice were 
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anaesthetised with CO2 prior to terminal bleeding, and livers were aseptically removed for 
bacterial analysis.  
Hepatic artery ligations: After midline abdominal incision the hepatic artery was prepared and 2 
ligatures placed, followed by section of the hepatic artery. In sham-operated animals, the hepatic 
artery was only exposed and ligatures placed but not sectioned. Splenectomies: Splenectomy 
was performed in 8-10 weeks old mice. After midline abdominal incision, the spleen was 
exposed and splenic artery and vein ligated before removal of the spleen and suture of the 
peritoneum and skin.  
Intra-mesenteric vein bacterial challenge: After midline abdominal incision, 107 E. coli JM83 or 
PBS in a volume of 100 µl were injected into the mesenteric veins of 8-10 weeks old mice with 
an insulin syringe followed by compression of the vessel for 2 minutes to stop bleeding. The 
peritoneum and skin were then closed with a suture. Animals were euthanized 8 hours after 
challenge and organs aseptically removed for plating and counting of CFUs.  
Preparation of clodronate liposomes: Clodronate liposomes were generated as described 
previously (17) and the effectiveness of depletion was validated by FACS. Briefly, a dry lipid 
mixture was solubilised with clodronate (Ostac, Boehringer, Mannheim) and the resulting 
multilammelar vesicles were filter-extruded. Unencapsulated clodronate was then removed by 
ultrafiltration followed by size exclusion chromatography. Liposomes were then re-concentrated 
(3-5 mg/ml) and sterile-filtered. C57BL/6 mice were i.v.-injected with liposomes containing 2-2.5 
mg clodronate 3 weeks after splenectomy and challenged with live E. coli K-12 into the tail vein 
3 days later to determine bacterial clearance capacity.  
Peripheral blood granulocyte numbers: Determination of granulocyte counts/microliter was 
performed using a VetABC animal blood counter (Medical Solution GmbH). 
From all animal models, fresh faecal pellets and serum were collected and used immediately or 
stored at -80°C prior to use.  
All animal experiments were approved by the local Animal Care Committee. 
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Colonisation with 14C labelled E. coli K-12. Germ-free C57BL/6 mice were monocolonized 
with 14C-labeled E. coli JS219 and liver biopsies were taken at 7, 24, 48 and 126 after 
colonization for culture on LB agar and to measure levels of radioactivity. Samples for 
radioactivity were dissolved in 1 ml of NCS II Tissue solubilizer (GE Healthcare) for a minimum 
of one hour at 56°C, at which time the pH level was neutralized with 100 µl of 100% glacial 
acetic acid and the sample was mixed with 18 ml of ULTIMA GoldTM liquid scintillation cocktail 
(PerkinElmer) prior to measuring radioactivity. 14C radioactivity levels in each sample were 
counted in a TRI-Carb 2300TR Liquid Scintillation Anaylzer (Packard) for a maximum time of 5 
minutes. Colorimetric quench curves were used to ensure accurate measuring of samples. 
Background levels of radioactivity were determined by measuring the levels of 14C in mesenteric 
lymph nodes and livers of germ-free C57BL/6 mice (n=2). 
E. coli HA107/JM83 mono-colonisation. Colonisation was performed as described previously 
(10). Briefly, D-Ala (200 µg/ml)/m-DAP (50 µg/ml)-supplemented LB cultures were aseptically 
inoculated from single colonies of E. coli strains HA107 or JM83 and incubated with shaking at 
160 rpm at 37°C for 18 hours. Bacteria were harvested under axenic conditions by centrifugation 
(15 min, 3500X g, 4°C), washed in sterile PBS and concentrated to a density of 2×1010 CFU/ml 
in PBS. The bacterial suspensions were sealed in sterile tubes and imported into flexible film 
isolators, where 500 µl (1010 CFU) were gavaged into the stomachs of germ-free Swiss Webster 
mice. Faecal samples exported from the isolator were bacteriologically analysed to monitor E. 
coli shedding and microbiological status of the inoculated mice. The same protocol was used to 
prepare bacteria for intra-venous injections.  
Bacteriology. Animals were euthanized and livers, spleens and mesenteric lymph nodes 
removed aseptically. For sampling of thoracic duct lymph, animals were gavaged with olive oil 2 
hours before analysis. The thoracic duct was then exposed and lymph sampled with a sterile 
micro-capillary for plating on agar plates. Organs were homogenised in 0.5% Tergitol/PBS using 
a Tissuelyser (Retsch MM400, 25Hz) and sterile stainless-steel ball bearing beads and 
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homogenates plated on supplemented agar plates for overnight culture at 37°C and CFU 
quantification. 
Isolation of faecal bacteria. Fresh faecal pellets were dissolved in 1 ml sterile PBS and 
streaked out onto LB and Blood agar plates. Plates were then incubated aerobically (LB) and 
anaerobically (Blood agar) for 24 or 48-72 hours respectively. Single colonies were grown in 
liquid brain-heart infusion medium (Oxoid, #CM0225) and used for bacterial FACS and 16S PCR 
to identify the bacterial species.  
16S rRNA Sequencing. 1 ml of a 5 ml overnight culture was pelleted by centrifugation at 7000 
rpm for 3 minutes Pellets were then dissolved in 250 µl direct PCR lysis reagent (Viagen Biotech 
Inc., # [102-T]) containing 5 µl proteinase K (Roche, # 3115887001). Samples were then 
incubated for 1 hour at 55°C followed by 1 hour at 85°C to inactivate proteinase K. 5 µl DNA 
template was then used for PCR, using 1 µl forward 10µM primer FD1 (AGA GTT TGA TCC 
TGG CTC AG), 1 µl forward 10µM primer FD2 (AGA GTT TGA TCA TGG CTC AG), 1 µl reverse 
10 µM primer RP1 (CG GTT ACC TTG TTA CGA CTT), 1µl dNTP (Promega, #U1515), 0.4 µl 
Taq polymerase (Promega, #M3175), 10 µl 5x buffer and 30.6 µl molecular water per reaction. 
PCR was performed according to the following set-up: 94°C 5 minutes 94°C 1 min, 43°C 1 min, 
72°C 2 min – repeat 35x, 72°C 7 min, 10°C forever. PCR purification was then performed using 
the MiniPrep kit (Qiagen, #28004) and DNA eluted in 10 µl water. DNA concentration was 
measured with a Nanodrop ND-1000 (Thermo Scientific) and 1 µl DNA plus 1 µl FD1 primer in 
18 µl molecular water was sent for 16S sequencing (Microsynth).  
NAFLD cohorts and controls. Serum samples from 2 different patient cohorts of NAFLD were 
collected in accordance with local ethical committees. The Basel cohort consisted of 28 patients 
with elevated aminotransferase levels and drinking less than 40 g (males) or 20 g (females) 
alcohol/week with biopsy-proven NAFLD (age (mean ± SD): 49 ± 16 years, sex (m/f): 18/10) and 
the Rome cohort consisted of 16 patients with biopsy-proven NASH drinking less than 20 g 
alcohol/day (age (mean ± SD): 50 ± 13 years, sex (m/f): 2/14) (26). All patients had biopsy-
	   18	  
proven NAFLD and alcohol intake was assessed by patient history. For Rome patients also one 
close relative was interviewed and an AUDIT test was performed and had to be less than 7 (27). 
Patients from the Basel cohort were further divided into a steatosis, NASH and cirrhosis group 
on the basis of the NAFLD activity score (NAS (28)). Frozen serum samples were stored at -
80°C prior to analysis. Healthy control samples were obtained from individuals interviewed to 
exclude acute illness or prior liver or intestinal disease. A selection of 4-16 precisely age- and 
sex-matched controls was used for each patient cohort. All experiments were performed in 
accordance with the local ethical committee approval and guidelines.  
ELISAs. Total concentrations of antibody isotypes in mouse or human serum were determined 
by sandwich ELISA. Mice: Coating antibodies were goat-anti-mouse IgG1, 2b, A and M 
(Serotech) and detection antibodies were HRP-conjugated anti-mouse IgG, IgM or IgA (Sigma). 
Standards were myeloma-derived purified IgG1, IgG2b, IgM (Invitrogen) and IgA (BD 
Pharmingen). Humans: IgG and IgA antibodies were determined using the Human IgG and IgA 
ELISA Quantitation Kit (Lubio Science, #E80-104, #E80-102).   
Bacterial FACS analysis. Bacterial FACS analysis was performed as described previously (10, 
20). Briefly, 5 ml LB cultures were inoculated from single colonies of plated bacteria and cultured 
overnight at 37°C without shaking. 1 ml of culture was gently pelleted for 3 mins at 7000 rpm in 
an Eppendorf minifuge and washed 3x with sterile-filtered PBS/2%BSA/Azide before re-
suspending at approximately 107 bacteria per ml. Mouse or human serum was diluted 1:10 in 
PBS/2%BSA/Azide and heat-inactivated at 60°C for 30 minutes. The serum solution was then 
spun at 13000 rpm in an Eppendorf minifuge for 10 minutes to remove any bacteria-sized 
contaminants and the supernatant was used to perform serial dilutions. 25 µl serum solution and 
25 µl bacterial suspension were then mixed and incubated at 4°C for 1 h. Bacteria were washed 
twice before re-suspending in monoclonal FITC-anti-mouse IgG2b or IgA, PE-anti-mouse IgG1 
and APC-anti-mouse IgM (BD Pharmingen, #559354, #550083, #553395, #550676) or 
Dyelight647-anti-human IgG, FITC-anti-human IgA (Jackson Immunoresearch). After a further 
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hour of incubation the bacteria were washed once with PBS/2% BSA/Azide and then re-
suspended in 2% PFA/PBS for acquisition on FACSArray using FSc and SSc parameters in 
logarithmic mode. Data were analysed using FlowJo software (Treestar, USA) and titres 
calculated by fitting 4-parameter logistic curves to each donor and determining the concentration 
of IgG or IgA required to give a median fluorescence intensity binding significantly above 
background. The inverse of this IgG or IgA concentration is shown, for ease of interpretation.  
Heatmap analysis. Heatmaps and correlation analysis was performed using R-software 
(http://www.r-project.org/). Heatmaps were generated for scaled, normalized titre data using an 
euclidean distance function with complete linkage clustering in R using the package "gplots 
version 2.8.0", function "heatmap.2".  
Serum lipocalin 2 ELISA. Lipocalin 2 values, as a marker of granulocyte activation and an 
acute phase-response, were determined by ELISA according to the manufacturer’s instructions 
with a few modifications (human: R&D systems, #DY1757, murine: R&D systems, #DY1857). 
Nunc Immuno Plates C96 Maxisorp (Milian, #430341) were coated with 50 µl capture antibody 
(1:200 in PBS) overnight at 4°C in a humidified chamber. After washing in PBS/Tween0.05% 
(Sigma, # P2287-500ML) and blocking in 150 µl PBS/BSA1% for 15 minutes at RT, samples and 
standard were added in 3-fold dose-titrations starting at 1:10 (serum and standard) or neat 
(faecal pellets, re-suspended in 1 ml PBS) and incubated overnight at 4°C in a humidified 
chamber. After washing in PBS/Tween0.05%, 50 µl detection antibody (1:200 in PBS/BSA2%) 
was added and plates incubated for 1 hour at RT. Plates were then washed in 
PBS/Tween0.05% and 100 µl HRP-Streptavidin (Biolegend, # 405210 1:1000 in PBS) was 
added for 1 hour. Plates were then washed and developed with 100 µl substrate (10 ml 
substrate buffer, 1 mg ABTS, 10 µl H2O2). OD was measured at 415nm and four-parameter 
curves generated to compare EC50 values of samples and standards.  
Histological analysis. Intestinal tissue samples were embedded in OCT, snap-frozen in liquid 
nitrogen, and stored at –80°C. Cryosections (5 µm) were mounted on glass slides, air dried for 2 
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h at room temperature, and stained with hematoxylin and eosin (H&E). Livers were fixed in 4% 
formaldehyde for 24 hours followed by ethanol 70% for 48 hours. Samples were then paraffin 
embedded, cut, and stained with H&E, F4/80 or Masson’s Trichrome respectively. 
Statistical analysis. Differences were analysed for statistical significance using Prism 4 for 
Macintosh (GraphPad software Inc). The details of the test carried out are indicated in figure 
legends. Where data was approximately normally distributed, values were compared using 
either a student t-test for single variable, or 2-way ANOVA for two variables. Approximate P 
values were computed for 2-way ANOVA. Where data were not normally distributed, (e.g. 
including bacterial CFU counts close to or equal to zero) non-parametric 2-tailed Mann-Whitney 
U tests were applied. In all cases, p < 0.05 was considered significant.  
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Figure Legends: 
Fig. 1. Firewall function of the liver in host-microbial mutualism. (A) Bacterial counts per gram of 
organ (liver = triangles, mesenteric lymph nodes = dots) is shown at the indicated time-points 
after oral gavage of NMRI mice with 1010 E. coli K-12 JM83 (filled symbols) and reversible 
colonizing E. coli HA107 (open symbols). (B) Bacterial products and live bacteria in the 
mesenteric lymph nodes (dots) and liver (triangles) after monocolonisation of germ-free C57BL/6 
mice with 14C-labelled E. coli JS219 at the indicated time-points after gavage. Radioactiave 
counts as a measure of bacterial products in liver and MLNs are shown as DPM on the left y-
axis (open dots and triangles) and live bacteria are shown as CFU/g tissue on the right y-axis 
(filled symbols). (C) Bacterial counts in the liver (triangles) and spleen (dots) 8 hours after intra 
mesenteric vein injection of PBS (open symbols) or 104 E. coli JM83. (D) Liver colony-forming 
units in 14-weeks old C57BL/6 mice after a DSS treatment regimen of 1%, 1.5% and 2% DSS in 
drinking water for 5 days each, followed by a normal water interval of 4 days each. Control mice 
received normal water throughout the experiment. Livers were then aseptically removed after 
the last drinking water period and CFUs assessed after anaerobic and aerobic culture on blood 
agar or LB plates respectively. Shown are the pooled counts from both types of plates. (E) 
Bacterial counts in the liver of splenectomised (squares) or sham-operated mice (dots) 18 hours 
after intra-venous injection of 107 E. coli JM83 (filled symbols) or PBS (open symbols) into the 
tail vein. (F) Bacterial counts per liver in C57BL/6 mice 48 hours after ligation of the hepatic 
artery (open circles) or sham operation (filled dots). All mice were intravenously challenged with 
107 E. coli K-12 and killed after 18 hours for plating of livers and spleens. All mice were 8-10 
weeks of age, each data point represents a single animal from one experiment and horizontal 
lines show means. The dashed lines show the detection limit. Unpaired t-test was used to 
compare the groups.  
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Fig. 2. Liver firewall function is compromised in liver disease independently of alterations in 
innate immunity. (A) Bacterial counts in peripheral blood at the indicated time-points after intra-
venous injection of 107 live E. coli into the tail vein of splenectoized and Kupffer-cell depleted 
(Clodronate, filled dots, solid line) or healthy control mice (open circles, dashed line). Kupffer 
cells were depleted 3 weeks after splenectomy in C57BL/6 mice by injecting clodronate 
liposomes 3 days prior to live bacterial challenge. Joining lines connect the means of each 
group. The horizontal dashed line represents the detection-limit. (B) Bacterial counts in 
peripheral blood at the indicated time-points after intra-venous injection of 107 live E. coli into the 
tail vein of bile-duct ligated (BDL, filled dots, solid lines) or sham-operated mice (open circles, 
dashed lines), 3-weeks after surgery. Shown are pooled data from two independent 
experiments. Joining lines connect the means of each group. The horizontal dashed line 
represents the detection-limit. (C) Bacterial counts per spleen of the same mice as in B, 6 hours 
after live bacterial challenge. Horizontal lines show means. (D) Bacterial counts in the spleen of 
CCl4 treated (black dots) or healthy control mice (open circles) 6 hours after live bacterial 
challenge with 107 E. coli into the tail vein. C57BL/6 mice were intra-peritoneally injected two 
times per week with CCl4 or olive oil respectively for 16 weeks. Horizontal lines show means. (E, 
F) Bacterial counts in peripheral blood (E) and spleen (F) in PBS or LPS injected mice 3 hours 
after injection of 107 live E. coli into the tail vein. All mice were treated 3 times per week with 
PBS alone or with 1 µg LPS from Salmonella typhimurium intraperitoneally and analysed 48h 
after the final treatment. All mice were then intravenously injected with 107 live E. coli. Bacterial 
counts were determined per 50 µl blood or organ. All mice were 8-10 weeks of age, each data 
point represents a single animal from one experiment and horizontal lines show means. 
Unpaired t-test was used to compare the groups.  
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Fig. 3. Increased systemic immune priming by intestinal commensal microbes in animal models 
with liver dysfunction. (A-D) Serum IgG1 (A, C) or IgG2b (B, D) titers against bacteria isolated 
from the mice’s own faeces (Clostridium sp.) in healthy control (black dots) and fibrotic 
C57BL/10 mice as determined by bacterial FACS. Liver fibrosis was induced by a 6 (A and B) or 
12 (C and D) weeks treatment with CCl4, intra-peritoneally administered two times per week or 
olive oil as control. (E, F) Serum IgG1 (E) and IgG2b (F) titers of the mice shown in A-D. IgG-
titers were calculated by fitting 4-parameter logistic curves to each sample and determining the 
concentration of IgG required to give a median fluorescence intensity binding above background 
staining. The inverse of this IgG concentration is shown, for ease of interpretation. Unpaired t-
test was used to compare the groups.  (G) Serum IgG1 titers against an autologous commensal 
bacterium (Lactobacillus murinus) isolated from the faeces in bile-duct ligated (BDL, open 
circles) or sham-operated control mice (black dots) 21 days after surgery. (H) Serum IgG-titers 
against an anaerobic bulk culture inoculated from the animals faeces 28 days after bile-duct 
ligation (filled dots) or sham-surgery (open circles) in rats. A-H Dose titrations of serum were 
incubated with the bacterial strain and specific IgG1- or IgG2b-binding visualized by FACS-
analysis. Data were then normalized to the total amount of IgG1 or IgG2b present in serum (x-
axis) as determined by ELISA. All curves represent individual mice from one of 2 independent 
experiments. 
Fig. 4. Disturbance of host-microbial mutualism in human patients with liver dysfunction. (A) 
Serum IgG titers against the indicated bacteria in NAFLD patients (open symbols) compared to 
age- and sex-matched healthy controls (filled dots). Pure cultures of the indicated bacteria were 
stained with dose-titrations of serum from patients or controls. Serum antibody coating of 
bacteria was visualised using monoclonal DyLight-conjugated anti-human IgG and quantified per 
bacterium by flow cytometry. Resulting MFI was plotted against total IgG added to the assay as 
determined by ELISA and IgG-titers calculated by fitting 4-parameter logistic curves to each 
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donor and determining the concentration of IgG required to give a median fluorescence intensity 
binding of 80. The inverse of this IgG concentration is shown, for ease of interpretation. Each 
point represents an individual subject and lines show means. Unpaired t-test or one-way 
ANOVA and Tukey post-test were used to compare the groups; *, p≤0.05, **; p≤0.01. (B) 
Cluster-analysis from Basel NAFLD patients with different stages of liver disease (steatosis = 
blue, NASH = yellow, cirrhosis = red) and age- and sex-matched healthy controls (green). 
Heatmaps were generated using an euclidean distance function with complete linkage clustering 
in the statistical package R using the package "gplots version 2.8.0", function "heatmap.2". Red 
indicates increased and blue decreased titers compared to the mean of the entire population. 
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Supplementary Materials: 
Figs. S1-S9 
 
Supplementary Figure Legends: 
Fig. S1. (A) Bacterial counts in peripheral and portal blood in 8-10 weeks old C57BL/6 mice at 
the indicated time-points after either oral gavage of 1010 or i.v. injection of 107 live E. coli. Each 
data point represents a single animal from one experiment. The dashed line indicates the 
detection limit. (B) Vascular supply of the liver and the spleen. Both liver (brown) and spleen 
(red) receive arterial blood (red) from the abdominal aorta via the hepatic or splenic artery 
respectively. The portal vein (blue) collects venous blood from the mesentery and delivers it to 
the liver for filtration. Venous blood leaving the spleen (blue) drains into the portal vein as well. 
Liver sinusoids architecture is shown on the left side. Hepatocytes are lined with a fenestrated 
endothelium. Liver Kupffer cells placed within this network rapidly phagocytose potentially 
harmful products. Hepatic stellate cells located underneath the endothelial layer are important 
for liver repair. 
 
Fig. S2. (A) Bacterial counts in peripheral blood (open circles) and spleen (filled dots) in 8-10 
weeks old C57BL/6 mice after 3 weeks of DSS treatment. Each data point represents one 
mouse from one experiment. The dashed line indicates the detection limit. (B) Representative 
FACS plots after anti-F4/80 staining on collagenase-digested Percoll-purified liver mononuclear 
cells of control (left) and clodronate liposome injected mice. Shown are means ± SD of n=3 mice 
per group.  
 
Fig. S3. (A-C) Bacterial counts in peripheral blood at the indicated time-points after intra-venous 
injection of 107 live E. coli into the tail vein of CCl4 treated (filled dots, solid lines) or olive-oil 
treated control mice (open circles, dashed lines) after 6, 12 or 16 weeks of treatment. Shown are 
	   29	  
pooled data from one (C) or two (A, B) independent experiments. Joining lines connect the 
means of each group. The horizontal dashed line represents the detection-limit. (D) Bacterial 
counts in the liver of 16 weeks CCl4 treated (black dots) or healthy control mice (open circles) 6 
hours after live bacterial challenge with 107 E. coli into the tail vein. C57BL/6 mice were intra-
peritoneally injected two times per week with CCl4 or olive oil respectively for 6, 12 or 16 weeks 
respectively. Horizontal lines show means. Unpaired t-test was used to compare the groups.  
 
Fig. S4. (A, B) Peripheral blood granulocytes and serum lipocalin 2 levels in sham-operated or 
BDL-treated mice before intra-venous challenge with live bacteria. Mice were analysed 3 weeks 
after surgery.  Each point represents one individual mouse from two independent experiments 
and horizontal lines show means. Unpaired t-test was used to compare the groups.  	  
Fig. S5. (A) Representative H&E stained liver sections of bile-duct ligated (BDL) or sham-
operated 10-weeks old NMRI mice 3 weeks after surgery. (B) Representative H&E stained liver 
sections of CCl4 treated or healthy control mice 6 or 12 weeks after treatment. (C) 
Representative Masson’s Trichrome stained liver sections of CCl4 treated or healthy control mice 
6, 12 or 16 weeks after treatment. (D) Representative F4/80 stained liver sections of CCl4 
treated or healthy control mice at week 12. CCl4 was dissolved in olive oil and administered 
intraperitoneally two times per week. Control mice received olive oil only. Note development of 
portal fibrosis and bile duct proliferation (arrows). 
 
Fig. S6. (A, B) Bacterial counts in peripheral blood and liver 3 hours after injection of 107 live E. 
coli into the tail vein. All mice were treated 3 times per week with PBS alone or with 1 µg LPS 
from Salmonella typhimurium intraperitoneally and analysed 48h after the final treatment. All 
mice were then intravenously injected with 107 live E. coli. Bacterial counts were determined per 
50 µl blood or organ. Each data point represents a single animal from one experiment and 
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horizontal lines show means. Unpaired t-test was used to compare the groups. (C) Bacterial 
counts in mesenteric lymph nodes or the thoracic duct lymph 6 hours after oral gavage with 1010 
live E. coli JM83 in healthy control (open circles) or CCl4 treated (filled dots) C57BL/6 mice. CCl4 
was dissolved in olive oil and administered intra-peritoneally two times per week over 6 weeks. 
Control mice received olive oil only. Each data point represents a single mouse from one 
experiment and horizontal lines show means. The dashed line indicates the detection limit. 
Unpaired t-test was used to compare the groups.  
	  
Fig. S7. (A) Representative H&E stained colons and small intestines of fibrotic (CCl4) or healthy 
control mice. CCl4 was dissolved in olive oil and administered intraperitoneally two times per 
week over 6 and 12 weeks respectively. Control mice received olive oil only. (B) H&E stained 
colons and small intestines of bile-duct ligated (BDL) or sham-operated 10-weeks old NMRI 
mice 3 weeks after surgery. Note development of oedema (asterisks), leukocyte infiltrate 
(arrows) and exudate (arrowheads) in BDL mice. (C) Faecal lipocalin 2 values in the same mice 
as in A as determined by ELISA. Each point represents one mouse from one experiment. The 
dashed line represents the detection-limit. Unpaired t-test was used to compare the groups.  
 
Fig. S8. (A, B) Serum IgG titers of the mice and rats shown in Fig. 3 G and H. IgG-titers were 
calculated by fitting 4-parameter logistic curves to each sample and determining the 
concentration of IgG required to give a median fluorescence intensity binding above background 
staining. The inverse of this IgG concentration is shown, for ease of interpretation. Each data 
point represents one mouse from one experiment. Unpaired t-test was used to compare the 
groups.   
 
Fig. S9. (A) IgA titers against the indicated bacteria in NAFLD patients (open symbols) 
compared to age- and sex-matched healthy controls (filled dots). Pure cultures of the indicated 
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bacteria were stained with dose-titrations of serum from patients or controls. Serum antibody 
coating of bacteria was visualised using monoclonal FITC-conjugated anti-human IgA and 
quantified per bacterium by flow cytometry. Resulting MFI was plotted against total IgA added to 
the assay as determined by ELISA and IgA-titers calculated by fitting 4-parameter logistic curves 
to each donor and determining the concentration of IgA required to give a median fluorescence 
intensity binding of 80. The inverse of this IgA concentration is shown, for ease of interpretation. 
Each point represents an individual subject and lines show means. Unpaired t-test or one-way 
ANOVA and Tukey post-test were used to compare the groups; *p≤0.05, **p≤0.01. (B) Cluster-
analysis from Rome NAFLD patients (blue) and healthy controls (yellow) for 8 different anti-
microbiota IgG and IgA titers. Heatmaps were generated using an euclidean distance function 
with complete linkage clustering in the statistical package R using the package "gplots version 
2.8.0", function "heatmap.2". Red indicates increased and blue decreased titers compared to the 
mean of the entire population. 
 	  	  	  
A CFU in MLN and liver
18h 42h 66h 18h 42h 66h
HA107 JM83
C
FU
 / 
g
C
10
10
10
E CFU in liver
Hepatic artery 
ligation
Sham
C
FU
 / 
g
p=0.005
F
2
3
4
18 hours after i.v. challenge
B
Balmer et al. Figure 1
200
400
600
800
1000
Bacterial products
R
ad
io
ac
tiv
ity
 p
er
 g
 ( 
  C
-D
P
M
)
14
Hours post-monocolonisation
C
FU
 / 
g
CFU in liver
Controls DSS
p = 0.02
D
103
104
102
101 detection limit
detection limit
unmanipulated mice
detection limit
C
FU
 / g 
   
 li
ve
r, 
   
 M
LN
10 2
10 3
10 4
10
10
2
3
C
FU
 / 
g
Liver Spleen
detection limit
p = 0.0002
CFU in liver and spleen
8 hours after mesenteric vein challenge
MLN
Liver
10 4 E. coli  
PBS control
Splenectomy Sham Splenectomy
no challenge10 7 E. coli i.v. 
C
FU
 / 
g
CFU in liver
18 hours after i.v. challenge
7 24 48 126
10 5
10 2
10 3
10 4
10 5
detection limit
     liver,     M
LN
after oral gavageafter oral gavage
0
500
1000
1500
detection limit
p=0.1
Balmer et al. Figure 2 
Time post-injection (h)
C
FU
 / 
50
µl
Blood bacterial burdenB
60.5
detection limit
p= 0.007
p= 0.005
3
101
102
103
104
100
A
Sham BDL
C
FU
 / 
sp
le
en
Spleen bacterial burden
p = 0.03
103
10
4
10
5
6 hours after i.v. challenge
PBS LPS
Blood bacterial burdenE
C
FU
 / 
50
µl
PBS LPS
Spleen bacterial burdenF
C
FU
 / 
 s
pl
ee
n
105
106
107
p=0.007 p=0.006
101
102
103
10
4
3 hours after i.v. challenge 3 hours after i.v. challenge
Spleen bacterial burdenC
6 hours after i.v. challenge
30 90 240 420
Time post-injection (min)
101
102
103
104
C
FU
 / 
5µ
l
Clodronate 
Control
detection limit
p= 0.02 p= 0.006
Blood bacterial burden
BDL
Sham
D
C
FU
 / 
sp
le
en
Control CCl4
105
10
6
104
103
p = 0.009
Balmer et al. Figure 3 
A B
C D
F
28 days bile duct ligation (rats)
IgG1 (μg/ml)
M
ea
n 
FI
  D
yl
ig
ht
-a
nt
i I
gG
10 1
10 2
10
3
10 0 10 1 10 210 -1 10 3
BDL
Baseline
IgG1 (μg/ml)
M
ea
n 
FI
  P
E
-a
nt
i I
gG
1
10 1
10 2
10 3
10 0
10 0 10 1 10 210 -1 10 3
BDL
Sham
E
10 0 10 110 -1 10 2
10 1
10 2
10 0M
ea
n 
FI
  P
E
-a
nt
i I
gG
1 CCl4
Ctrl
10 0 10 110 -1 10 2
10 1
10 2
10 0
CCl4
Ctrl
IgG1 (μg/ml)
IgG1 (μg/ml)
M
ea
n 
FI
  P
E
-a
nt
i I
gG
1
10 0 10 110 -1 10 2
IgG2b (μg/ml)
M
ea
n 
FI
  F
IT
C
-a
nt
i I
gG
2b
10 1
10 2
10 3 CCl4
Ctrl
10 0 10 110 -1 10 2
IgG2b (μg/ml)
M
ea
n 
FI
  F
IT
C
-a
nt
i I
gG
2b
10 1
10 2
10 3 CCl4
Ctrl
21 days bile duct ligation (mice)
6 weeks CCl4 6 weeks CCl4
12 weeks CCl4 12 weeks CCl4
HG
0.1
1
10
Ctrl
6 weeks
CCl4 Ctrl
12 weeks
CCl4
p=0.02
Ig
G
1 
Ti
te
r
0.1
1
10
Ctrl
6 weeks
CCl4 Ctrl
12 weeks
CCl4
Ig
G
2b
 T
ite
r
detection limit
detection limit
p=0.0005
Balmer et al. Figure 4
B
. v
ul
ga
tu
s 
Ig
A
B
. a
do
le
sc
en
tis
 Ig
A
B
. t
he
rm
op
hi
liu
m
 Ig
A
B
. d
is
ta
so
ni
us
 Ig
A
B
. t
he
rm
op
hi
liu
m
 Ig
G
B
. v
ul
ga
tu
s 
Ig
G
B
. d
is
ta
so
ni
us
 Ig
G
B
. a
do
le
sc
en
tis
 Ig
G
Green:  Healthy controls
Red:  Cirrhosis
Yellow:  NASH
Blue:  Steatosis 
Serum antibody-titers
-3 -1 1 3
Value
0
25
Color Key
C
ou
nt
an
ti-
E
.c
ol
i H
A
11
6 
Ig
G
 ti
te
r 
E. coli IgG
NAFLD Controls
an
ti-
B
.fr
ag
ili
s 
Ig
G
 ti
te
r 
Bacteroides fragilis IgG
NAFLD Controls
10 2
10 3
10 4
10 2
10 3
10 1
p = 0.009p = 0.004
Bifidobacterium thermophilium IgG
an
ti-
B
.th
er
m
op
hi
liu
m
 Ig
G
 ti
te
r 
NAFLD Controls
10 1
10 2
10 3
10 4 p = 0.05
Klebsiella oxytoca IgG
an
ti-
K
.o
xy
to
ca
 Ig
G
 ti
te
r
Steatosis NASH Cirrhosis Controls
A
B
10 1
10 2
10 3
10 4
10 0
**
*
Balmer et al. Supplementary Figure 1
Splenic artery
Hepatic artery
Splenic vein
Portal vein
Abdominal aorta
Inferior mesenteric vein
Superior mesenteric vein
Hepatic vein
Vena cava
SPLEEN
HEART
LIVER
Hepatic artery
Portal vein
Hepatic vein
Kupffer cells
Hepatocytes
Endothelium
Stellate cells
A
1h 4h 8h 1h 4h 8h
oral gavage i.v. injection
peripheral blood
portal blood
10
10
10
2
3
4
10 1
C
FU
 / 
50
µl
 b
lo
od
detection limit
B
Balmer et al. Supplementary Figure 2 
DSS treatmentA B
Control DSS
C
FU
 / 
50
µl
102
103
104
105
106
107
blood
spleen
10
2
103
104
105
106
107
C
FU
 / spleen
detection limit
100 101 102 103 104
F4/80
24±4%
Control
100 101 102 103 104
F4/80
4±3%
Clodronate
Balmer et al. Supplementary Figure 3 
Blood bacterial burdenBA Blood bacterial burden
8 weeks CCL4 treatment
60.5 3
C
FU
 / 
50
µl
101
102
103
100 detection limit
12 weeks CCL4 treatment
Time post-injection (h)
101
102
103
104
105
106
60.5 3
Time post-injection (h)
C
FU
 / 
50
µl
Blood bacterial burdenC
16 weeks CCL4 treatment
p= 0.002
p= 0.009 p= 0.02
CCL4
Sham
CCL4
Sham
CCL4
Sham
Liver bacterial burden
16 weeks CCL4 treatment
D
C
FU
 / 
m
g 
liv
er
Control CCl4
p = 0.0002
60.5 3
Time post-injection (h)
101
102
103
100
104
detection limit
C
FU
 / 
50
µl
103
10
4
102
Balmer et al. Supplementary Figure 4 
GranulocytesA
Sham BDL
G
ra
nu
lo
cy
te
s 
(1
0 
 /µ
l)
3
0
5
10
15
20
B Lipocalin 2
Sham BDL
Li
po
ca
lin
 2
 (n
g/
m
l)
p < 0.0001 p = 0.0002
103
10 4
10 2
unmanipulated mice unmanipulated mice
A Control
100µm
BDL
100 µm 100 µm
Control CCl4B 
100 µm 100 µm
6 weeks
12 weeks
Control CCl4C 
100 µm 100 µm
6 weeks
12 weeks
16 weeks
Balmer et al. Supplementary Figure 5
Control CCl4D 
12 weeks
100 µm 100 µm
Balmer et al. Supplementary Figure 6 
C
Control CCl4
Bacterial counts
after oral gavage
C
FU
 / 
g Thoracic duct
C
FU
 / m
l
M
LN
10 1
10 0
10 1
10 0
detection limit
PBS LPS
C
FU
/5
0µ
l
Blood bacterial burdenA
PBS LPS
Liver bacterial burdenB
C
FU
/m
g
103
104
105
103
104
105
p=0.06 p=0.06
30 minutes after i.v. challenge 3 hours after i.v. challenge
ns
100 µm100 µm 100 µm100 µm
Faecal lipocalin 2
Sham BDL
Li
po
ca
lin
 2
 (n
g/
g)
p = 0.008
101
102
103
detection limit
unmanipulated mice
B
Balmer et al. Supplementary Figure 7
        Small intestine
Sham
BDL
Small intestineColon
Control
CCl4
A
CColon
Small intestineColon
6 weeks of CCl4-treatment 12 weeks of CCl4-treatment
100 µm100 µm
*
BA
p=0.1
Ig
G
1 
Ti
te
r
Ig
G
 T
ite
r
detection limit
0.1
1
Sham BDL
1
10
100
Baseline BDL
p=0.02
Balmer et al. Supplementary Figure 8 
Balmer et al. Supplementary Figure 9
A
E. coli IgA
NAFLD Controls
an
ti-
L.
ga
rv
ie
ae
 Ig
A 
tit
er
 
Lactococcus garvieae IgA
NAFLD Controls
an
ti-
E
. c
ol
i H
A
11
6 
Ig
A 
tit
er
 
Bifidobacterium thermophilium IgA
an
ti-
B
.th
er
m
op
hi
liu
m
 Ig
A 
tit
er
 
Steatosis NASH Cirrhosis Controls Steatosis NASH Cirrhosis Controls
Bacteroides vulgatus IgA
an
ti-
B
.v
ul
ga
tu
s 
Ig
A 
tit
er
 *** *
E
. c
ol
i N
is
sl
e 
Ig
A
K
le
bs
ie
lla
 s
p.
 Ig
A
B
. t
he
ta
 Ig
A
B
. t
he
ta
 Ig
G
B
. a
do
le
sc
en
tis
 Ig
A
B
. t
he
rm
op
ili
um
 Ig
A
B
. f
ra
gi
lis
 Ig
A
La
ct
oc
oc
cu
s 
sp
. I
gG
K
le
bs
ie
lla
 s
p.
 Ig
G
B
. t
he
rm
op
hi
liu
m
 Ig
G
E
. c
ol
i N
is
sl
e 
Ig
G
La
ct
oc
oc
cu
s 
sp
. I
gA
B
. f
ra
gi
lis
 Ig
G
B
. a
do
le
sc
en
tis
 Ig
G
E
. c
ol
i H
A
11
6 
Ig
G
E
. c
ol
i H
A
11
6 
Ig
A
Yellow:  Healthy Controls
Blue:  NAFLD 
Serum antibody-titers
-2 0 2
Value
0
14
Color Key
C
ou
nt
B
10 2
10 3
10 4
10 5
10 1
10 2
10 3
10 4
10 1
10 2
10 3
10 0
10 1
10 2
10 3
10 0
***
*****
p = 0.004 p = 0.1
